Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-grapefruit juice interactions.

G C Kane1, J J Lipsky

  • 1Department of Internal Medicine, Mayo Clinic, Rochester, Minn. 55905, USA.

Mayo Clinic Proceedings
|September 20, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Update on the management of atherosclerotic renal artery disease.

Minerva cardioangiologica·2009
Same author

KATP channels confer survival advantage in cocaine overdose.

Molecular psychiatry·2007
Same author

K(ATP) channel pharmacogenomics: from bench to bedside.

Clinical pharmacology and therapeutics·2007
Same author

Deficiency of heme oxygenase-1 impairs renal hemodynamics and exaggerates systemic inflammatory responses to renal ischemia.

Kidney international·2007
Same author

Is simulation based medicine training the future of clinical medicine?

European review for medical and pharmacological sciences·2007
Same author

Angiotensin II antagonism fails to ameliorate bleomycin-induced pulmonary fibrosis in mice.

The European respiratory journal·2005
Same journal

Thyroid Dysfunction and the Risk of Clinically Relevant Depression: A Longitudinal Cohort Study.

Mayo Clinic proceedings·2026
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
See all related articles

Grapefruit juice inhibits drug metabolism by affecting cytochrome P-450 3A4 and P-glycoprotein. This interaction can increase medication levels, potentially leading to adverse effects for patients.

Area of Science:

  • Pharmacology
  • Drug Metabolism

Background:

  • Grapefruit juice is a common beverage with known interactions with medications.
  • The intestinal cytochrome P-450 3A4 system is crucial for the first-pass metabolism of many drugs.
  • P-glycoprotein, an intestinal transporter, also handles numerous cytochrome P-450 3A4 substrates.

Purpose of the Study:

  • To review the mechanisms of drug-grapefruit juice interactions.
  • To identify specific medications involved in these interactions.
  • To discuss the clinical significance of these interactions.

Main Methods:

  • Literature review of studies on grapefruit juice and drug interactions.
  • Analysis of proposed mechanisms involving enzyme inhibition and transporter effects.
  • Examination of clinical data on altered drug concentrations and adverse events.

Related Experiment Videos

Main Results:

  • Grapefruit juice inhibits intestinal cytochrome P-450 3A4, increasing serum concentrations of susceptible drugs.
  • Interactions are notable with cyclosporine, calcium channel blockers, and statins.
  • The P-glycoprotein transporter may also be affected, further influencing drug levels.
  • Elevated drug concentrations can lead to increased dose-dependent adverse effects.

Conclusions:

  • Grapefruit juice significantly impacts the metabolism and transport of various medications.
  • Understanding these drug-grapefruit juice interactions is crucial for patient safety.
  • Clinicians should consider these interactions when prescribing medications metabolized by cytochrome P-450 3A4 or transported by P-glycoprotein.